Out-Licensing Partner Search and Outreach: How Evaluate Helped a Biotech Secure Pharma Interest

A UK-based biotech lacked internal resources to find partners for out-licensing two oncology assets in Phase 1 and Phase 2. Evaluate's Business Development & Licensing team built "a dynamic model to compare and rank potential partners" using proprietary databases, then executed targeted outreach to the top 50 candidates with personalized communications to key decision-makers. The campaign achieved a "30% response rate – well above industry benchmarks," with three major pharmaceutical companies actively reviewing the assets for licensing.

The customer is anonymised in Norstella’s own case study — not withheld by us.

Norstella is a holding company merging several pharma-intelligence brands — Citeline (trial intelligence), Evaluate (forecasting), MMIT (payer/formulary data) and Panalgo (real-world analytics) — into one data asset.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.